This site is intended only for healthcare professionals resident in the Republic of Ireland
Click here for CIBINQO Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.1
CIBINQO has been extensively studied in 7 phase 3 trials, including 1 ongoing long-term extension study evaluating safety and efficacy in patients with moderate-to-severe AD2
CIBINQO offers flexibility so you can tailor treatment to meet the individual needs of your patients
View images of patients with moderate-to-severe AD from the JADE clinical trials.
Consistent safety profile in patients with moderate-to severe AD studied across JADE clinical trials
A quick reference guide that outlines what you need to know about starting patients on CIBINQO
Consistent safety profile with >3100 adults and adolescents studied across JADE clinical trials2-6,11,12
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023